Thus, it is likely that the difference in the choice of diluent for the ELISA protocol accounts in part for the discrepant findings of Michael et al. [14], and their inability to detect significantly elevated MIF serum levels in their prostate cancer group. Here, MIF is linked to prostate cancer.